Skip to main content
editorial
. 2006 Nov 7;12(41):6674–6677. doi: 10.3748/wjg.v12.i41.6674

Table 2.

Incidence of LAR for selected baseline factors

Factors Variables (n) % LAR P
Preoperative
Age (yr) < 40 (53) vs ≥ 40 (151) 12 vs 6 0.03
Gender Men (102) vs women (102) 8 vs 8 0.79
Disease: Viral Yes (77) vs No (127) 9 vs 6 0.41
Total bilirubin (mg/L) < 50 (100) vs ≥ 50 (104) 8 vs 7 0.72
MELD score < 10 (123) vs ≥ 10 (81) 7 vs 9 0.57
Blood type match Identical (163) vs compatible (41) 8 vs 5 0.5
Gender match Yes (91) vs No (113) 9 vs 6 0.48
Donor age (yr) < 40 (84) vs ≥ 40 (120) 10 vs 6 0.32
HLA-A mismatch (n) 0 (75) vs 1 or 2 (128) 9 vs 6 0.64
HLA-B mismatch (n) 0 (38) vs 1 or 2 (166) 11 vs 7 0.41
HLA-DR mismatch (n) 0 (43) vs 1 or 2 (161) 5 vs 8 0.44
T-LCX Negative (195) vs positive (9) 8 vs 0 0.39
B-LCX Negative (116) vs positive (88) 5 vs 7 0.71
Operative
Anhepatic time (min) < 150 (116) vs ≥ 150 (88) 8 vs 7 0.8
Blood loss (mL/kg) < 100 (88) vs ≥ 100 (116) 7 vs 8 0.8
Graft weight/SLV (%) < 50 (69) vs ≥ 50 (135) 7 vs 7 0.97
Postoperative
Immunosuppressive regimen FK (166) vs CsA (38) 32 vs 2 < 0.0001
Proceeding CMV infection Yes (82) vs No (116) 7 vs 8 0.91
Early acute rejection Yes (61) vs No (143) 11 vs 6 0.14

LAR: Late onset acute rejection; MELD: Model for end stage liver disease; HLA-n: Human leukocyte antigen n allele; LCX: Lymphocytotoxic crossmatch; SLV: Standard liver volume; CMV: Cytomegalovirus.